Luyten, BE
Frank Luyten, Kraainem BE
Patent application number | Description | Published |
---|---|---|
20090117652 | USE OF CXCL6 CHEMOKINE IN THE PREVENTION OR REPAIR OF CARTILAGE DEFECTS - The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation. | 05-07-2009 |
20090123927 | ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body. | 05-14-2009 |
20090162328 | IN VIVO ASSAY AND MOLECULAR MARKERS FOR TESTING THE PHENOTYPIC STABILITY OF CELL POPULATIONS AND SELECTED CELL POPULATIONS FOR AUTOLOGOUS TRANSPLANTATION - An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×10 | 06-25-2009 |
20100068715 | MARKER GENES FOR USE IN THE IDENTIFICATION OF CHONDROCYTE PHENOTYPIC STABILITY AND IN THE SCREENING OF FACTORS INFLUENCING CARTILAGE PRODUCTION - The present invention relates to a set of genes which can be used to predict the potential of a cell population to form cartilage when implanted in vivo. The set of markers is used inter alia as a quality control of cells and in screening assays to evaluate the impact of compounds and conditions on the cartilage forming ability of cells. | 03-18-2010 |
20110158960 | ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body. | 06-30-2011 |
20110256100 | SECRETED MODULAR CALCIUM BINDING PROTEIN FOR INTRACELLULAR MODULATION OF BONE MORPHOGENETIC PROTEIN SIGNALING - A method for modulating Bone Morphogenetic Protein (BMP) signaling activity in a cell or tissue of a vertebrate subject is provided which comprises administering a polynucleotide or polypeptide encoding a Secreted Modular Calcium Binding Protein (SMOC) polypeptide, or a conservatively modified variant, derivative, or analog thereof, in an amount effective to activate intracellular Mitogen Activated Protein (MAP) kinase activity and to reduce BMP signaling activity in the cell or tissue of the vertebrate subject. Methods for treating joint disorders in a mammalian subject are provided. | 10-20-2011 |
Geert Luyten, Averbode BE
Patent application number | Description | Published |
---|---|---|
20090059742 | OPTICAL DISK DRIVE WITH SPHERICAL ABERRATION MEASUREMENT AND METHOD OF MEASURING SPHERICAL ABERRATION IN AN OPTICAL DISK DRIVE - The invention relates to an optical disk drive. The optical disk drive has an objective lens to be driven by a focus actuator with a focus offset for focusing an incident beam onto an optical disk into a spot with a spherical aberration, and a processor to derive a first and a second characteristic from a sensor output signal and obtain a spherical aberration correction value (SA) from a pre-determined function, the pre-determined function defining a spherical aberration correction value in dependence on a focus offset difference value (ΔFO). The focus offset difference value (ΔFO) is determined from a difference between a second optimal focus offset at which the second characteristic is optimal and a first optimal focus offset at which the first characteristic is optimal. The spherical aberration correction value (SA) can be used to achieve a correction to the spherical aberration of the spot. | 03-05-2009 |
Jan Luyten, Molenstede BE
Patent application number | Description | Published |
---|---|---|
20090280022 | TITANIUM, TITANIUM ALLOY AND NiTi FOAMS WITH HIGH DUCTILITY - A method for manufacturing a high ductility Ti-, Ti-alloy or NiTi-foam, meaning a compression strain higher than 10%, includes: preparing a powder suspension of a Ti-, NiTi- or Ti-alloy powder, bringing the said powder suspension into a desired form by gelcasting to form a green artefact. The method also includes a calcination step wherein the green artefact is calcined, and sintering the artifact. The calcination step includes a slow heating step wherein said green artefact is heated at a rate lower or equal to 20° C./hour to a temperature between 400° C. and 600° C. and the Ti-, NiTi- or Ti-alloy powder has a particle size less than 100 μm. A high ductility Ti-, Ti-alloy or NiTi foam, with a compression higher than 10%, with a theoretical density less than 30%, pore size (cell size) between 50 to 1000 μm can be obtained with such a method. | 11-12-2009 |
Jan Roger Luyten, Molenstede BE
Patent application number | Description | Published |
---|---|---|
20110064784 | METHOD FOR PRODUCING A THREE-DIMENSIONAL MACROPOROUS FILAMENT CONSTRUCT BASED ON PHASE INVERSION AND CONSTRUCT THEREBY OBTAINED - The present invention relates to a method for producing a three-dimensional macroporous filament construct comprising interconnected microporous filaments showing a suitable surface roughness and microporosity. The method comprises the steps of: a) preparing a suspension comprising particles of a predetermined material, a liquid solvent, one or more binders and optionally one or more dispersants, b) depositing said suspension in the form of filaments in a predetermined three-dimensional pattern, preferably in a non-solvent environment, thereby creating a three-dimensional filament-based porous structure, c) inducing phase inversion, whereby said filaments are transformed from a liquid to a solid state, by exposing said filaments during the deposition of the filaments with a non-solvent vapour and to a liquid non-solvent, d) thermally treating the structure of step d) by calcining and sintering said structure. The invention further provides a three-dimensional macroporous filament construct comprising interconnected microporous filaments showing a specific surface roughness and microporosity. The invention also relates to various uses of the construct, including its use for the manufacture of a biomedical product, such as a synthetic bone implant or bone graft. | 03-17-2011 |
Marc Luyten, Schilde BE
Patent application number | Description | Published |
---|---|---|
20100037563 | PACKAGING - Packaging for a pallet ( | 02-18-2010 |
Walter Luyten, Bertem BE
Patent application number | Description | Published |
---|---|---|
20100284935 | MARKERS AND DIAGNOSTIC METHODS FOR METASTASIS - The present invention provides methods for the prediction, prognosis and/or diagnosis of metastasis. The present invention also provides proteins (or the related nucleic acid sequences) or protein expression profiles which are predictive and/or prognostic for metastasis. The invention thus relates to the use of said proteins and the corresponding amino acid or nucleic acid sequences for the prediction, prognosis or diagnosis of metastasis. | 11-11-2010 |